Differential expression of the bcl-2 oncogene in human basal cell carcinoma.
The bcl-2 protein increases cell longevity and reduces apoptosis. Expression of the bcl-2 oncogene is reported in certain low grade neoplasms including basal cell carcinomas (BCCs). The authors postulated that the indolent variants of BCC, namely, the superficial and circumscribed subtypes, might exhibit greater bcl-2 expression than their aggressive counterparts, and used a monoclonal antibody to identify its protein product in formalin-fixed tissue from 30 BCCs. Expression of bcl-2, observed in 28 to 30 BCCs, was greatest in indolent-growth BCCs and weakest in the aggressive-growth variants (P = .005). Variable bcl-2 expression is seen in BCC and may be integral to both its pathogenesis and its biological behavior.
Crowson
A N
AN
Central Medical Laboratories, Misericordia General Hospital, Winnipeg, Manitoba, Canada.
Magro
C M
CM
Kadin
M E
ME
Stranc
M
M
D000911:Antibodies, Monoclonal; D001360:Avidin / Q000032:analysis; D001706:Biopsy; D001710:Biotin / Q000032:analysis; D002280:Basal Cell Carcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007124:Immunoenzyme Techniques; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D011519:Proto-Oncogenes / Q000235:genetics* / Q000502:physiology; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
D000911:Antibodies, Monoclonal; D011518:Proto-Oncogene Proteins; D001360:Avidin; D001710:Biotin